MAP2K7 and cancer: We found that higher expression levels of MXD3 were associated with decreased sensitivity of cancer cell lines to trametinib (a MEK inhibitor), docetaxel, RDEA119 (a MEK inhibitor), PD-0325901 (a MEK inhibitor), and bleomycin but led to increased activities of I-BET-762, WZ3105, QL-XI-92, KIN001-102, GSK690693, GSK1070916, NPK76-II-72–1, QL-X-138, and navitoclax in various cancer cell lines (Fig. 7A).